AUTHOR=Dagkonaki Anastasia , Avloniti Maria , Evangelidou Maria , Papazian Irini , Kanistras Ioannis , Tseveleki Vivian , Lampros Fotis , Tselios Theodore , Jensen Lise Torp , Möbius Wiebke , Ruhwedel Torben , Androutsou Maria-Eleni , Matsoukas John , Anagnostouli Maria , Lassmann Hans , Probert Lesley TITLE=Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions JOURNAL=Frontiers in Immunology VOLUME=11 YEAR=2020 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.575451 DOI=10.3389/fimmu.2020.575451 ISSN=1664-3224 ABSTRACT=
CNS autoantigens conjugated to oxidized mannan (OM) induce antigen-specific T cell tolerance and protect mice against autoimmune encephalomyelitis (EAE). To investigate whether OM-peptides treat EAE initiated by human MHC class II molecules, we administered OM-conjugated murine myelin oligodendrocyte glycoprotein peptide 35-55 (OM-MOG) to humanized HLA-DR2b transgenic mice (DR2b.Ab°), which are susceptible to MOG-EAE. OM-MOG protected DR2b.Ab° mice against MOG-EAE by both prophylactic and therapeutic applications. OM-MOG reversed clinical symptoms, reduced spinal cord inflammation, demyelination, and neuronal damage in DR2b.Ab° mice, while preserving axons within lesions and inducing the expression of genes associated with myelin (